Tc99m Tilmanocept
Lymphatic Mapping (Breast Cancer, Melanoma)
Key Facts
About Navidea Biopharmaceuticals
Navidea Biopharmaceuticals' mission is to advance precision medicine by developing targeted diagnostics and therapies that identify undetected disease sites. Its core achievement is the Manocept platform, which led to the FDA-approved radiopharmaceutical Tc99m Tilmanocept (Lymphoseek®) for lymphatic mapping, the rights to which were sold to Cardinal Health in a deal worth up to $325 million. The company's strategy has been to leverage this platform across multiple inflammatory and oncologic indications, but its execution has been severely hampered by persistent financial instability, culminating in a Chapter 11 bankruptcy filing in October 2025, casting significant doubt on its future viability.
View full company profileAbout Navidea Biopharmaceuticals
Navidea Biopharmaceuticals' mission is to advance precision medicine by developing targeted diagnostics and therapies that identify undetected disease sites. Its core achievement is the Manocept platform, which led to the FDA-approved radiopharmaceutical Tc99m Tilmanocept (Lymphoseek®) for lymphatic mapping, the rights to which were sold to Cardinal Health in a deal worth up to $325 million. The company's strategy has been to leverage this platform across multiple inflammatory and oncologic indications, but its execution has been severely hampered by persistent financial instability, culminating in a Chapter 11 bankruptcy filing in October 2025, casting significant doubt on its future viability.
View full company profile